RxDoctor Payments Data

Farhad Irani, MD

Internal Medicine · Naples, FLNPI 1982767265

Payments from drug & device makers

$4,006in general payments, 2019–2025

Across 216 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$1K
  • Novo Nordisk$955
  • AstraZeneca$288
  • Novartis$232
  • AbbVie$202
  • Abbott$144
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$3,97299%
  • Education$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,006 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$692,174
Medicare patients
840
Services billed
17,234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide131$174,329
EliquisApixaban138$157,445
JardianceEmpagliflozin93$141,036
FarxigaDapagliflozin Propanediol59$83,461
XareltoRivaroxaban61$73,207
Synjardy XrEmpagliflozin/Metformin Hcl32$47,357
MounjaroTirzepatide31$43,108
DescovyEmtricitabine/Tenofov Alafenam12$26,512
JanuviaSitagliptin Phosphate12$20,434
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$18,953
Breo ElliptaFluticasone/Vilanterol16$15,685
SynjardyEmpagliflozin/Metformin Hcl11$15,043
MyrbetriqMirabegron11$14,677
Repatha SureclickEvolocumab11$9,831
Tresiba Flextouch U-100Insulin Degludec12$9,041

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy$1,008$203,437136 claims
Novo NordiskOzempic$955$174,329131 claims
PfizerEliquis$61$157,445138 claims
AstraZenecaFarxiga$288$83,46159 claims
Johnson & JohnsonXarelto$57$73,20761 claims
Lilly USA, LLCMounjaro$107$43,10831 claims
GSKTrelegy Ellipta, Breo Ellipta$51$34,63733 claims
GileadDescovy$29$26,51212 claims
MerckJanuvia$116$20,43412 claims
AbbVieSynthroid$202$5,12178 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$92$4,598530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →